CLAIMS

1. A liquid pharmaceutical formulation comprising an antibody as an active ingredient, glycine and sucrose, wherein the antibody specifically binds colony stimulating factor-1 receptor (CSF1R) and wherein the antibody comprises:

a) a light chain comprising CDR1, CDR2 and CDR3 as defined in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively; and

b) a heavy chain comprising CDR1, CDR2, and CDR3 as defined in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

2. A liquid pharmaceutical formulation according to claim 1 comprising glycine at a concentration of 20 mM to 200 mM.

3. A liquid pharmaceutical formulation according to claims 1 or 2 comprising sucrose at a concentration of 20 mM to 200 mM.

4. A liquid pharmaceutical formulation according to any preceding claim comprising at least 50 mg/ml antibody.

5. A liquid pharmaceutical formulation according to any preceding claim comprising a surfactant.

6. A liquid pharmaceutical formulation according to claim 5 comprising 0.01 % to 10% Polysorbate 80.

7. A liquid pharmaceutical formulation according to claim 1 wherein the antibody specifically binds human CSF1R.

8. A liquid pharmaceutical formulation according to claim 1 or 7 wherein the antibody neutralizes CSF1R.

9. A liquid pharmaceutical formulation according to any preceding claim wherein the antibody is a humanized or human antibody.

10. A liquid pharmaceutical formulation according to any preceding claim wherein the antibody comprises a variable light chain as defined in SEQ ID NO: 7 and a variable heavy chain as defined in SEQ ID NO: 11.

11. A liquid pharmaceutical formulation according to any preceding claim comprising:

- 40 - 60 mM citrate buffer at pH 5;
- 100 - 150 mM glycine;
- 100 - 150 mM sucrose; and
- 0.02 - 0.1% polysorbate 80.